David T. Curiel

David T. Curiel

Washington University in St. Louis

H-index: 125

North America-United States

About David T. Curiel

David T. Curiel, With an exceptional h-index of 125 and a recent h-index of 39 (since 2020), a distinguished researcher at Washington University in St. Louis, specializes in the field of gene therapy, adenovirus, virotherapy.

His recent articles reflect a diverse array of research interests and contributions to the field:

Mucosal vaccine-induced cross-reactive CD8+ T cells protect against SARS-CoV-2 XBB.1.5 respiratory tract infection

Elucidating expression of a corrective enzyme for mucopolysaccharidoses type I through administration of an adenoviral vector targeted to endothelial cells

Coronavirus vaccine constructs and methods of making and using same

Engineering a Novel Modular Adenoviral mRNA Delivery Platform Based on Tag/Catcher Bioconjugation

Oncolytic adenoviral vector and methods of use

In Vitro and In Vivo Efficacy of a Stroma-Targeted, Tumor Microenvironment Responsive Oncolytic Adenovirus in Different Preclinical Models of Cancer

Mucosal adenoviral-vectored vaccine boosting durably prevents XBB. 1.16 Infection in nonhuman primates

A bivalent ChAd nasal vaccine protects against SARS-CoV-2 BQ. 1.1 and XBB. 1.5 infection and disease in mice and hamsters

David T. Curiel Information

University

Position

School of Medicine

Citations(all)

61903

Citations(since 2020)

9178

Cited By

55185

hIndex(all)

125

hIndex(since 2020)

39

i10Index(all)

661

i10Index(since 2020)

196

Email

University Profile Page

Washington University in St. Louis

Google Scholar

View Google Scholar Profile

David T. Curiel Skills & Research Interests

gene therapy

adenovirus

virotherapy

Top articles of David T. Curiel

Title

Journal

Author(s)

Publication Date

Mucosal vaccine-induced cross-reactive CD8+ T cells protect against SARS-CoV-2 XBB.1.5 respiratory tract infection

Nature immunology

Baoling Ying

Tamarand L Darling

Pritesh Desai

Chieh-Yu Liang

Igor P Dmitriev

...

2024/2/9

Elucidating expression of a corrective enzyme for mucopolysaccharidoses type I through administration of an adenoviral vector targeted to endothelial cells

Molecular Genetics and Metabolism

Sarah Hurt

Steven Q Le

Alexander Sorensen

David T Curiel

Patricia I Dickson

2024/2/1

Coronavirus vaccine constructs and methods of making and using same

2023/7/20

Engineering a Novel Modular Adenoviral mRNA Delivery Platform Based on Tag/Catcher Bioconjugation

Viruses

Kexin Geng

Paul J Rice-Boucher

Elena A Kashentseva

Igor P Dmitriev

Zhi Hong Lu

...

2023/11/20

Oncolytic adenoviral vector and methods of use

2023/1/3

In Vitro and In Vivo Efficacy of a Stroma-Targeted, Tumor Microenvironment Responsive Oncolytic Adenovirus in Different Preclinical Models of Cancer

International journal of molecular sciences

Ana Alfano

Eduardo GA Cafferata

Mariela Gangemi

Alejandro Nicola Candia

Cristian M Malnero

...

2023/6/10

Mucosal adenoviral-vectored vaccine boosting durably prevents XBB. 1.16 Infection in nonhuman primates

bioRxiv

Matthew Gagne

Barbara J Flynn

Shayne F Andrew

Dillon R Flebbe

Anna Mychalowych

...

2023/11/8

A bivalent ChAd nasal vaccine protects against SARS-CoV-2 BQ. 1.1 and XBB. 1.5 infection and disease in mice and hamsters

bioRxiv

Baoling Ying

Tamarand L Darling

Pritesh Desai

Chieh-Yu Liang

Igor P Dmitriev

...

2023/5/4

Conjugate systems and methods of use thereof

2023/10/19

In vivo editing of the pan-endothelium by immunity evading simian adenoviral vector

Biomedicine & Pharmacotherapy

Reka Lorincz

Aluet Borrego Alvarez

Christopher J Walkey

Samir A Mendonça

Zhi Hong Lu

...

2023/2/1

Adenoviral vectors infect B lymphocytes in vivo

Molecular Therapy

Paul J Rice-Boucher

Samir Andrade Mendonça

Aluet Borrego Alvarez

Alexandria J Sturtz

Reka Lorincz

...

2023/9/6

Phase III Pivotal comparative clinical trial of intranasal (iNCOVACC) and intramuscular COVID 19 vaccine (Covaxin®)

npj Vaccines

Chandramani Singh

Savita Verma

Prabhakar Reddy

Michael S Diamond

David T Curiel

...

2023/8/18

Immunogenicity and tolerability of BBV154 (iNCOVACC®), an intranasal SARS-CoV-2 vaccine, compared with intramuscular Covaxin® in healthy adults: a randomised, open-label, Phase …

Chandramani Singh

Savita Verma

Prabhakar Reddy

Michael S Diamond

David T Curiel

...

2023/1/31

Encapsulation of AAVs into protein vault nanoparticles as a novel solution to gene therapy’s neutralizing antibody problem

bioRxiv

Logan Thrasher Collins

Wandy Beatty

Buhle Moyo

Michele Alves-Bezerra

Ayrea Hurley

...

2023/11/29

Synthetic biology design as a paradigm shift toward manufacturing affordable adeno-associated virus gene therapies

Logan Thrasher Collins

Selvarangan Ponnazhagan

David T Curiel

2023/1/10

Convection enhanced delivery of the oncolytic adenovirus delta24-RGD in patients with recurrent GBM: a phase I clinical trial including correlative studies

Clinical Cancer Research

Erik HP Van Putten

Anne Kleijn

Victor W Van Beusechem

David Noske

Cor HJ Lamers

...

2022/4/14

An adenoviral mediated gene therapy for mucopolysaccharidosis type I

Molecular Genetics and Metabolism

Sarah Hurt

Steven Q Le

Samir Mendonca

Patricia Dickson

David T Curiel

2022/2/1

Bi-allelic CAMSAP1 variants cause a clinically recognizable neuronal migration disorder

The American Journal of Human Genetics

Reham Khalaf-Nazzal

James Fasham

Katherine A Inskeep

Lauren E Blizzard

Joseph S Leslie

...

2022/11/3

A Novel Piggyback Strategy for mRNA Delivery Exploiting Adenovirus Entry Biology

Viruses

Myungeun Lee

Paul J Rice-Boucher

Logan Thrasher Collins

Ernst Wagner

Lorenzo Aulisa

...

2022/9/30

Efficient genome editing achieved via plug-and-play adenovirus piggyback transport of Cas9/gRNA complex on viral capsid surface

ACS nano

Zhi Hong Lu

Jie Li

Igor P Dmitriev

Elena A Kashentseva

David T Curiel

2022/6/24

See List of Professors in David T. Curiel University(Washington University in St. Louis)